Rabbit Monoclonal Cyclin D1 antibody - conjugated to HRP. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 4 publications.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
WB | |
---|---|
Human | Tested |
Mouse | Tested |
Rat | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/5000 | Notes - |
Species Rat | Dilution info 1/5000 | Notes - |
Species Human | Dilution info 1/5000 | Notes - |
Select an associated product type
The protein expressed by the CCND1 gene acts as a regulatory component of the cyclin D1-CDK4 (DC) complex, which phosphorylates and inhibits retinoblastoma (RB) protein family members, including RB1, regulating the cell cycle during the G(1)/S transition. Phosphorylation of RB1 allows the transcription factor E2F to dissociate from the RB/E2F complex, enabling transcription of E2F target genes responsible for G(1) phase progression. In early G(1) phase, it hypophosphorylates RB1. Cyclin D-CDK4 complexes integrate various mitogenic and antimitogenic signals. The protein also serves as a substrate for SMAD3, phosphorylating it in a cell-cycle-dependent manner to repress its transcriptional activity, and forms part of the cyclin D1/CDK4/CDKN1B complex necessary for nuclear translocation and activity. Additionally, it exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters, independent of the cell cycle. This supplementary information is collated from multiple sources and compiled automatically.
BCL1, PRAD1, CCND1, G1/S-specific cyclin-D1, B-cell lymphoma 1 protein, BCL-1 oncogene, PRAD1 oncogene, BCL-1
Rabbit Monoclonal Cyclin D1 antibody - conjugated to HRP. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 4 publications.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk blocking buffer before being incubated with ab190564 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-Cyclin D1 antibody [EPR2241] (ab190564) at 1/5000 dilution
Lane 1: MCF7 Whole Cell Lysate at 10 µg
Lane 2: RAW 264.7 Whole Cell Lysate at 10 µg
Lane 3: PC12 Whole cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 34 kDa
Observed band size: 34 kDa
Exposure time: 4min
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab190564 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-Cyclin D1 antibody [EPR2241] (ab190564) at 1/5000 dilution
Lane 1: MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate at 10 µg
Lane 2: RAW 264.7 (Mouse leukaemic monocyte macrophage cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 34 kDa
Observed band size: 34 kDa
Exposure time: 1min
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab190564 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-Cyclin D1 antibody [EPR2241] (ab190564) at 1/5000 dilution
All lanes: PC12 (Rat adrenal pheochromocytoma cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 34 kDa
Observed band size: 34 kDa
Exposure time: 1min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com